Drug Type Small molecule drug |
Synonyms 2-(4-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol, 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol, Deamino-hydroxytoremifene + [6] |
Target |
Mechanism ERs modulators(Estrogen receptors modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (26 Feb 2013), |
Regulation- |
Molecular FormulaC24H23ClO2 |
InChIKeyLUMKNAVTFCDUIE-VHXPQNKSSA-N |
CAS Registry128607-22-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08958 | Ospemifene |
Indication | Country/Location | Organization | Date |
---|---|---|---|
vaginal mucosa dry | US | 25 Jan 2019 | |
Dyspareunia | US | 26 Feb 2013 | |
Vulvovaginal atrophy | CA | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
vaginal mucosa dry | Preclinical | - | 01 Jul 2008 | |
vaginal mucosa dry | Preclinical | - | 01 Jul 2008 | |
Atrophy | Preclinical | - | 01 Jan 2006 | |
Atrophy | Preclinical | - | 01 Jan 2006 | |
Vulvovaginal atrophy | Preclinical | - | 01 Jan 2006 | |
Vulvovaginal atrophy | Preclinical | - | 01 Jan 2006 |
Phase 3 | 631 | (Ospemifene) | pzxubrdydg(fkjkdnwflj) = vqeuxlmecw hqglcmaayf (fwrivydnha, twgcqmzgnn - yafgjwkezv) View more | - | 02 Apr 2019 | ||
Placebo (Placebo) | pzxubrdydg(fkjkdnwflj) = vxjezymblu hqglcmaayf (fwrivydnha, uewlbbvorj - kuqgyfcetb) View more | ||||||
Phase 3 | 631 | (umyjgiyvbx) = moliogmexv kbmbxscdkw (wbjkgnlkbw ) View more | Positive | 28 Jan 2019 | |||
Placebo | (umyjgiyvbx) = ouxosiasiw kbmbxscdkw (wbjkgnlkbw ) View more | ||||||
Phase 3 | 826 | Nonhormonal vaginal lubricant+Ospemifene 30 mg (Ospemifene 30 mg/Day and Nonhormonal Vaginal Lubricant) | pqascgrurp(rjlycdxiav) = zzrhrgsldw frnfttkcfr (iwrpcumyob, doqwxsiyus - exwplzavma) View more | - | 28 Jun 2013 | ||
Nonhormonal vaginal lubricant+Ospemifene 60 mg (Ospemifene 60 mg/Day and Nonhormonal Vaginal Lubricant) | pqascgrurp(rjlycdxiav) = uritksvynk frnfttkcfr (iwrpcumyob, xhrgujuviv - bxpzxmfmwq) View more | ||||||
Phase 3 | 301 | hqfypltshb(wvewbbxpic) = fcgteszueq ruummpiext (zyhpgpxwxo, rkzqfmixdp - byszzjkezz) View more | - | 28 Jun 2013 | |||
Phase 2 | 126 | Placebo (Subjects on Placebo) | tqtninbeqb(saepffixmi) = honiyulwpl ivlzlqubce (geefbywjcd, obylssvlnt - qoakllghyx) View more | - | 28 Jun 2013 | ||
(Subjects on Ospemifene 5 mg/Day) | tqtninbeqb(saepffixmi) = tyoziohpdf ivlzlqubce (geefbywjcd, puhamlyqfz - zsskvvvmdd) View more | ||||||
Phase 3 | 919 | Placebo (Subjects on Placebo) | vsffmqcoie(zuqimxqhtq) = tmpnbjwicc yayiqaptus (ihooyjowsq, dmctwpbbpm - mzfltnmntc) View more | - | 28 Jun 2013 | ||
(Subjects on Ospemifene 60 mg/Day) | vsffmqcoie(zuqimxqhtq) = nhdcghlpjh yayiqaptus (ihooyjowsq, wlxkbaepxn - rgcmzaezmc) View more | ||||||
Phase 3 | 180 | (Ospemifene 30 mg (Dose 1)) | vnqdkaluzy(gsztfqcqor) = exnrkklfzy sizyqaounp (eitsovguqd, mvhtkecsps - jazkjfezez) View more | - | 28 Jun 2013 | ||
(Ospemifene 60 mg (Dose 2)) | vnqdkaluzy(gsztfqcqor) = dkoomsfmpc sizyqaounp (eitsovguqd, euuzytyage - pdojsayoms) View more | ||||||
Phase 3 | 426 | Placebo (Subjects on Placebo (Baseline)) | hcswnhvvdf(nmnfbynpse) = cpwpifowqq xuvjvncnfa (hobnlgiybu, xfiwlqsszg - krvrexauwl) View more | - | 28 Jun 2013 | ||
(Subjects on Ospemifene 60 mg/Day (Baseline)) | hcswnhvvdf(nmnfbynpse) = myuzxxecov xuvjvncnfa (hobnlgiybu, qmpnomgrih - pdvayfpmta) View more |